Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sargassum cristaefolium extract (SCE) is a botanical extract derived from the brown seaweed Sargassum cristaefolium, containing a variety of bioactive compounds including flavonoids, alkaloids (specifically beta-carboline alkaloids), and tannins. In preclinical models of migraine, SCE has demonstrated the ability to increase serotonin (5-HT) levels by inhibiting monoamine oxidase (MAO) and blocking 5-HT reuptake. Furthermore, the extract exhibits anti-platelet activity by reducing platelet counts and inhibiting aggregation, which are key factors in migraine pathogenesis. Its broader pharmacological profile includes antioxidant, anti-inflammatory, and analgesic properties, making it a candidate for the prevention and treatment of neurovascular headaches.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sargassum cristaefolium extract.